Immunovant, Inc.
IMVT
Jodie situation report
Immunovant, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- R&D costs for rheumatology increased $24.9M, reflecting expenses from clinical trials of IMVT-1402 in D2T RA and SjD.
Invalidation: The isolated read changes if IMVT's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind IMVT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ROIVRoivant Sciences Ltd.partnerMay 20, 2026 ▾
“108 Table of Contents Unallocated costs include: • personnel-related expenses, such as salaries, stock-based compensation and benefits, for research and development personnel; • costs allocated to us under our services agreements with Roivant Sciences Ltd.”
Depended on by
ROIVRoivant Sciences Ltd.partnerMay 20, 2026 ▾
“Vant / Licensor Product Candidate Milestones Royalties Priovant / Pfizer Brepocitinib • Mid-tens-of-millions sales milestone payment if aggregate net sales in a given year exceed a mid-hundreds-of-millions amount • Tiered sub-teens royalty on net sales Immuno…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IMVT is currently a Leader in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.